Depletion of the lncRNA RP11-567G11.1 inhibits pancreatic cancer progression
Background: Pancreatic cancer is one of the most lethal malignancies, as demonstrated by its 5-year survival rate of less than 10%. The poor response of pancreatic cancer to conventional therapeutics, especially against cancer stem cells (CSCs), is the primary obstacle to improving patient survival....
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-04-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332218331354 |
id |
doaj-42088af59fd749b5b9af2782a2aa992d |
---|---|
record_format |
Article |
spelling |
doaj-42088af59fd749b5b9af2782a2aa992d2021-05-20T07:35:12ZengElsevierBiomedicine & Pharmacotherapy0753-33222019-04-01112Depletion of the lncRNA RP11-567G11.1 inhibits pancreatic cancer progressionRanglang Huang0Wanpin Nie1Kai Yao2Jing Chou3Department of General Surgery, The Third Xiangya Hospital of Central South University, China; Department of Anesthesia, The Third Xiangya Hospital of Central South University, ChinaDepartment of General Surgery, The Third Xiangya Hospital of Central South University, China; Department of Anesthesia, The Third Xiangya Hospital of Central South University, ChinaDepartment of General Surgery, The Third Xiangya Hospital of Central South University, China; Department of Anesthesia, The Third Xiangya Hospital of Central South University, ChinaDepartment of General Surgery, The Third Xiangya Hospital of Central South University, China; Department of Anesthesia, The Third Xiangya Hospital of Central South University, China; Corresponding author at: Department of Anesthesia, The Third Xiangya Hospital of Central South University, Tongzipo Road No.138, Changsha, Hunan, 410011, China.Background: Pancreatic cancer is one of the most lethal malignancies, as demonstrated by its 5-year survival rate of less than 10%. The poor response of pancreatic cancer to conventional therapeutics, especially against cancer stem cells (CSCs), is the primary obstacle to improving patient survival. Emerging evidence indicates that the long non-coding RNA (lncRNA) RP11-567G11.1 is up-regulated in pancreatic cancer tissues and that its expression is associated with poor prognosis. This study aimed to elucidate the mechanism by which RP11-567G11.1 influences survival in pancreatic cancer. Methods: We evaluated the expression of RP11-567G11.1 in pancreatic cancer tissues via in situ hybridization. We also constructed RP11-567G11.1 knockdown cell models and used CCK8 and flow cytometry to detect the function of this lncRNA. Western blotting and qPCR were used to detect the expression levels of factors related to RP11-567G11.1. Results: The results illustrated that RP11-567G11.1 was significantly up-regulated in poorly differentiated pancreatic cancer tissues as compared to its expression in non-tumor tissues. Additionally, depletion of RP11-567G11.1 in pancreatic cancer cells inhibited proliferation and cell cycle progression, induced apoptosis, suppressed the stem cell-like phenotype, and increased sensitivity to gemcitabine. Also depletion of RP11-567G11.1 in pancreatic cancer cells inhibited factors downstream of the NOTCH signaling pathway. Conclusion: RP11-567G11.1 plays a crucial role in pancreatic cancer. Importantly, depletion of RP11-567G11.1 boosts the sensitivity of pancreatic cancer cells to gemcitabine, suggesting that this lncRNA is a promising target for pancreatic cancer treatment.http://www.sciencedirect.com/science/article/pii/S0753332218331354RP11-567G11.1Cancer stem cellPancreatic cancerGemcitabineNotch signaling |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ranglang Huang Wanpin Nie Kai Yao Jing Chou |
spellingShingle |
Ranglang Huang Wanpin Nie Kai Yao Jing Chou Depletion of the lncRNA RP11-567G11.1 inhibits pancreatic cancer progression Biomedicine & Pharmacotherapy RP11-567G11.1 Cancer stem cell Pancreatic cancer Gemcitabine Notch signaling |
author_facet |
Ranglang Huang Wanpin Nie Kai Yao Jing Chou |
author_sort |
Ranglang Huang |
title |
Depletion of the lncRNA RP11-567G11.1 inhibits pancreatic cancer progression |
title_short |
Depletion of the lncRNA RP11-567G11.1 inhibits pancreatic cancer progression |
title_full |
Depletion of the lncRNA RP11-567G11.1 inhibits pancreatic cancer progression |
title_fullStr |
Depletion of the lncRNA RP11-567G11.1 inhibits pancreatic cancer progression |
title_full_unstemmed |
Depletion of the lncRNA RP11-567G11.1 inhibits pancreatic cancer progression |
title_sort |
depletion of the lncrna rp11-567g11.1 inhibits pancreatic cancer progression |
publisher |
Elsevier |
series |
Biomedicine & Pharmacotherapy |
issn |
0753-3322 |
publishDate |
2019-04-01 |
description |
Background: Pancreatic cancer is one of the most lethal malignancies, as demonstrated by its 5-year survival rate of less than 10%. The poor response of pancreatic cancer to conventional therapeutics, especially against cancer stem cells (CSCs), is the primary obstacle to improving patient survival. Emerging evidence indicates that the long non-coding RNA (lncRNA) RP11-567G11.1 is up-regulated in pancreatic cancer tissues and that its expression is associated with poor prognosis. This study aimed to elucidate the mechanism by which RP11-567G11.1 influences survival in pancreatic cancer. Methods: We evaluated the expression of RP11-567G11.1 in pancreatic cancer tissues via in situ hybridization. We also constructed RP11-567G11.1 knockdown cell models and used CCK8 and flow cytometry to detect the function of this lncRNA. Western blotting and qPCR were used to detect the expression levels of factors related to RP11-567G11.1. Results: The results illustrated that RP11-567G11.1 was significantly up-regulated in poorly differentiated pancreatic cancer tissues as compared to its expression in non-tumor tissues. Additionally, depletion of RP11-567G11.1 in pancreatic cancer cells inhibited proliferation and cell cycle progression, induced apoptosis, suppressed the stem cell-like phenotype, and increased sensitivity to gemcitabine. Also depletion of RP11-567G11.1 in pancreatic cancer cells inhibited factors downstream of the NOTCH signaling pathway. Conclusion: RP11-567G11.1 plays a crucial role in pancreatic cancer. Importantly, depletion of RP11-567G11.1 boosts the sensitivity of pancreatic cancer cells to gemcitabine, suggesting that this lncRNA is a promising target for pancreatic cancer treatment. |
topic |
RP11-567G11.1 Cancer stem cell Pancreatic cancer Gemcitabine Notch signaling |
url |
http://www.sciencedirect.com/science/article/pii/S0753332218331354 |
work_keys_str_mv |
AT ranglanghuang depletionofthelncrnarp11567g111inhibitspancreaticcancerprogression AT wanpinnie depletionofthelncrnarp11567g111inhibitspancreaticcancerprogression AT kaiyao depletionofthelncrnarp11567g111inhibitspancreaticcancerprogression AT jingchou depletionofthelncrnarp11567g111inhibitspancreaticcancerprogression |
_version_ |
1721435546963673088 |